Wipfli Financial Advisors LLC Takes $36,000 Position in Qiagen (NYSE:QGEN)

Wipfli Financial Advisors LLC purchased a new position in shares of Qiagen (NYSE:QGEN – Get Rating) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 874 shares of the company’s stock, valued at approximately $36,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Captrust Financial Advisors raised its position in shares of Qiagen by 23.1% in the 1st quarter. Captrust Financial Advisors now owns 1,232 shares of the company’s stock valued at $60,000 after buying an additional 231 shares in the last quarter. Cigna Investments Inc. New lifted its holdings in shares of Qiagen by 7.5% during the 2nd quarter. Cigna Investments Inc. New now owns 4,495 shares of the company’s stock worth $210,000 after acquiring an additional 312 shares during the period. Bridgewater Associates LP lifted its holdings in shares of Qiagen by 1.0% during the 2nd quarter. Bridgewater Associates LP now owns 46,043 shares of the company’s stock worth $2,173,000 after acquiring an additional 451 shares during the period. Toroso Investments LLC lifted its holdings in shares of Qiagen by 11.0% during the 1st quarter. Toroso Investments LLC now owns 7,392 shares of the company’s stock worth $362,000 after acquiring an additional 735 shares during the period. Finally, Quadrant Capital Group LLC lifted its holdings in shares of Qiagen by 19.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,619 shares of the company’s stock worth $218,000 after acquiring an additional 742 shares during the period. Institutional investors own 58.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on QGEN shares. Berenberg Bank upped their price target on shares of Qiagen from €53.91 ($58.60) to €54.60 ($59.35) in a report on Friday, November 11th. StockNews.com assumed coverage on shares of Qiagen in a research note on Wednesday, October 12th. They issued a “buy” rating for the company. William Blair reissued a “market perform” rating on shares of Qiagen in a research note on Tuesday, November 8th. Morgan Stanley assumed coverage on shares of Qiagen in a research note on Tuesday, October 18th. They issued an “equal weight” rating for the company. Finally, Oddo Bhf downgraded shares of Qiagen from an “outperform” rating to a “neutral” rating in a research note on Monday, October 10th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Qiagen presently has a consensus rating of “Hold” and an average target price of $54.80.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $49.86 on Thursday. The firm has a 50 day simple moving average of $49.33 and a 200 day simple moving average of $46.54. The company has a market cap of $11.32 billion, a price-to-earnings ratio of 24.81, a PEG ratio of 1.38 and a beta of 0.41. Qiagen has a one year low of $40.38 and a one year high of $51.30. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.84 and a quick ratio of 1.62.

Qiagen (NYSE:QGEN – Get Rating) last released its quarterly earnings results on Monday, November 7th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.08. The firm had revenue of $499.63 million during the quarter, compared to the consensus estimate of $479.99 million. Qiagen had a net margin of 20.83% and a return on equity of 18.43%. Research analysts predict that Qiagen will post 2.32 earnings per share for the current fiscal year.

Qiagen Profile

(Get Rating)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.